From MarketBeat:



Jefferies Financial Group initiated coverage on Dianthus Therapeutics with a “buy” rating and a $22.00 price target on the stock. Other analysts also commented on the company, including Wedbush, Raymond James, and Guggenheim. Dianthus Therapeutics opened at $11.44 on Tuesday, with a 52-week low of $5.28 and a high of $14.46. On November 9th, it was reported that the company had an EPS of ($3.78) and a revenue of $0.92 million.

In other news, Fairmount Funds Management Llc acquired 24,670 shares of Dianthus Therapeutics, while institutions like Citigroup Inc. and FMR LLC also bought shares. The stock is currently owned by 47.53% institutional investors. Dianthus Therapeutics is a clinical-stage biotechnology company that designs, develops, and delivers monoclonal antibodies for autoimmune and inflammatory diseases, and is in phase 1 clinical trials for patients with various conditions.

Jefferies Financial Group sets “buy” rating and $22.00 price target, Dianthus Therapeutics opens at $11.44, with a 52-week low/high of $5.28/$14.46, and the company reported a Q3 EPS of ($3.78) and revenue of $0.92 million. Fairmount Funds Management Llc acquired 24,670 shares of Dianthus Therapeutics, and various institutional investors have also bought stakes in the company. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company developing monoclonal antibodies for autoimmune and inflammatory diseases, currently in phase 1 clinical trials.



Read more: Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at Jefferies Financial Group